Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Spotlight: Pertinax Pharma, Closing In On Wound Care With Slow-Release CHX Tech

Executive Summary

A UK drug-delivery firm is bringing its antimicrobial material to the global wound-care market. Pertinax Pharma, a Bristol University spin-out, is the developer of a slow-release technology that provides controlled and sustained delivery of the antiseptic chlorhexidine.

You may also be interested in...



Acelity Buys Crawford To Create Wound-Care Powerhouse

Acelity has agreed to acquire Crawford Healthcare for an undisclosed price to expand its wound care portfolio. Crawford's wound-dressing portfolio includes the KerraMax Care, KerraFoam, and KerraCel brands, complementing Acelity's advanced wound dressing line-up, which includes the Promogran Prisma Matrix collagen dressing, the Tielle dressings, and Adaptic dressings. The deal also includes Crawford's research and development and manufacturing facilities in Chesire, UK.

Pertinax Pharma Eyes Wound Care Growth With New Hire

Emerging drug delivery firm Pertinax has hired a new business development manager to lead commercialization of its technology in the wound care market.

Anti-Infection Material Start-Up Taps Pharma Veteran For Chairman

Briston University spin-out and developer of an antimicrobial material Pertinax Pharma has appointed Nigel Brooksby as chairman.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT122376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel